Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sangamo Biosciences ( (SGMO) ) has shared an announcement.
Sangamo Therapeutics faced legal challenges over a stock increase amendment, but the Delaware Court of Chancery validated the voting process, clearing uncertainties. Meanwhile, in collaboration with Pfizer, Sangamo presented promising results from the Phase 3 AFFINE trial for a gene therapy targeting hemophilia A, showing significant reductions in bleeding rates. These developments are pivotal for investors tracking Sangamo’s strategic moves and the broader gene therapy market.
See more insights into SGMO stock on TipRanks’ Stock Analysis page.
